title: Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates.
abstract: BACKGROUND
  In clinical practice, bone mineral density (BMD) determined by dual-energy x-ray absorptiometry is used to monitor response to osteoporosis therapy. However, 1 to 2 yr are usually required to assess patients' BMD responses. The possibility of earlier indicators of a response or nonresponse to treatment, such as changes in bone turnover markers (BTMs), is of interest to physicians and patients.
  
  
  METHODS
  In this post hoc analysis of women treated with once-weekly bisphosphonates, we examined the association of tertile percentage change from baseline in BTMs at 3 or 6 months and association of several baseline clinical characteristics with 24-month percentage change from baseline in BMD and with percentage of patients showing BMD nonresponse (defined as BMD loss at two or more of four sites) at 24 months. Multivariable analysis was performed to determine which factors were independently associated with BMD nonresponse.
  
  
  RESULTS
  Patients in the tertile with the greatest decrease in each of the BTMs had the greatest mean increase in BMD and the lowest percentage of BMD nonresponders at 24 months. Several characteristics were independently associated with BMD nonresponse, including smaller 3-month reductions from baseline in serum C-terminal telopeptide of type 1 collagen, bone-specific alkaline phosphatase, and N-terminal propeptide of type 1 procollagen; younger age of menopause; a family history of osteoporosis; and higher baseline trochanteric BMD. Baseline BTMs were not predictive of 24-month BMD response to therapy. The strongest associations were for changes in BTMs with treatment.
  
  
  CONCLUSIONS
  In groups of patients, short-term changes in markers of bone turnover appear to be predictors of longer term BMD response and nonresponse to bisphosphonate therapy.
authors.affiliation: Thier 1051, Endocrine Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. sburnett-bowie@partners.org
authors.forename: Sherri-Ann M
authors.initials: SM
authors.lastname: Burnett-Bowie
authors.forename: Kenneth
authors.initials: K
authors.lastname: Saag
authors.forename: Anthony
authors.initials: A
authors.lastname: Sebba
authors.forename: Anne E
authors.initials: AE
authors.lastname: de Papp
authors.forename: Erluo
authors.initials: E
authors.lastname: Chen
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Rosenberg
authors.forename: Susan L
authors.initials: SL
authors.lastname: Greenspan
mesh_terms: D015992:Body Mass Index; D015519:Bone Density / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D004164:Diphosphonates / Q000627:therapeutic use*; D005006:Ethnicity; D005260:Female; D050723:Fractures, Bone / Q000453:epidemiology; D006801:Humans; D008875:Middle Aged; D010024:Osteoporosis / Q000517:prevention & control; D017698:Postmenopause / Q000502:physiology*; D044469:Racial Groups
chemical_list: D004164:Diphosphonates